ISCO Signed a Clinical Service Agreement with the Florey Institute of Neuroscience and Mental Health

CARLSBAD, CA — (Marketwired) — 12/23/15 — International Stem Cell Corporation (OTCQB: ISCO) (www.internationalstemcell.com) a clinical stage biotechnology company developing novel stem cell-based therapies, announced today that it has entered into a master clinical research agreement with the Florey Institute of Neuroscience and Mental Health (Florey) to conduct Phase I/IIa clinical trial, dose escalation trial […]

Read More >>

ISCO Receives Authorization to Initiate Phase I/IIa Clinical Trial of ISC-hpNSC for the Treatment of Parkinson’s Disease

Regulatory submission (CTX) cleared for Phase I dose escalation trial in patients with moderate to severe Parkinson’s disease CARLSBAD, CA–(Marketwired – December 14, 2015) – International Stem Cell Corporation (OTCQB: ISCO), a leader in using pluripotent stem cells in regenerative medicine, announced today that the Therapeutics Goods Administration (TGA) of Australia cleared a regulatory submission […]

Read More >>

ISCO Announces Launch Plans for New Nano-Compound Products

CARLSBAD, CA–(Marketwired – December 01, 2015) – International Stem Cell Corporation (OTCQB: ISCO), a California-based biotechnology company developing novel stem cell-based therapies and biomedical products, announced today that its wholly-owned subsidiary Lifeline Skin Care, Inc. (Lifeline) will launch its next generation skin care product based on a breakthrough nano-compound technology in time for December holiday season. The initial […]

Read More >>